Ensysce Biosciences Acquires Signature Therapeutics for Undisclosed Sum
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8e88ba3-04d7-42cf-8469-5cd352f14cc8 - Date
1/20/2016 - Company Name
Signature Therapeutics - Mailing Address
1731 Embarcadero Road Palo Alto, CA 94303 USA - Company Description
Signature Therapeutics creates value through our ability to efficiently advance relatively low risk drug discovery and development programs, which address large markets with clearly defined unmet needs. - Website
http://www.signaturerx.com - Transaction Type
M&A - Transaction Amount
Undisclosed - Transaction Round
- Proceeds Purposes
- M&A Terms
Ensysce Biosciences and Signature Therapeutics are pleased to announce completion of a formal merger on Dec. 31, 2015, naming Dr. Lynn Kirkpatrick as CEO. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Financial terms of the transaction were not disclosed.
